SIPONIMOD
| Brand name | MAYZENT |
|---|---|
| Active ingredient | SIPONIMOD |
| Strength | EQ 0.25MG BASE |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2019 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12533340 | April 2036 | use U-4407 |
| 11944602 | April 2036 | use U-3889 |
| 12071402 | January 2032 | product |
| 8492441 | November 2030 | use U-2511 |
| 7939519 | August 2028 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.